In addition, linsitinib, an IGF‐1R inhibitor, has been found to significantly inhibit the growth and metastasis of HCC mediated by BACH1 when used in combination with defactinib, a PTK2 inhibitor.74, 75. This evidence concerns the gene IGF1R and hepatocellular carcinoma.